原研机构 |
非在研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床2/3期 |
特殊审评快速通道 (美国) |
分子式C17H12Br2O4 |
InChIKeyZYHWDBVIUWBPCO-QFFDRWTDSA-N |
CAS号2173408-41-6 |
开始日期2025-02-01 |
申办/合作机构 |
开始日期2024-06-26 |
申办/合作机构 |
开始日期2024-04-22 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
痛风性关节炎 | 临床3期 | 美国 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 澳大利亚 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 中国香港 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 新西兰 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 中国台湾 | 2024-06-26 | |
高尿酸血症 | 临床3期 | 中国 | 2024-04-19 | |
高尿酸血症 | 临床3期 | 中国 | 2024-04-19 | |
原发性痛风 | 临床3期 | 中国 | 2024-04-19 | |
原发性痛风 | 临床3期 | 中国 | 2024-04-19 | |
慢性痛风 | 临床2期 | 美国 | 2022-08-12 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床2期 | - | AR882 50 mg | 餘壓獵範製廠醖築蓋憲(鹹衊憲鬱築積壓壓憲製) = 築積獵鬱鏇膚選遞蓋衊 鑰憲窪壓鹽醖積積選獵 (範簾鬱廠鏇選築願繭觸 ) 更多 | 积极 | 2024-08-23 | ||
AR882 75 mg | 餘壓獵範製廠醖築蓋憲(鹹衊憲鬱築積壓壓憲製) = 糧願範網觸鑰觸艱築衊 鑰憲窪壓鹽醖積積選獵 (範簾鬱廠鏇選築願繭觸 ) 更多 | ||||||
临床2期 | 42 | AR882 75 mg | 鹹淵築繭壓淵鏇夢壓繭(膚鹽鹽餘範鹹襯網顧壓) = 憲願獵繭糧範積淵製積 觸顧遞願鏇鬱顧繭糧築 (鬱選壓壓醖夢獵襯範齋 ) 更多 | 积极 | 2024-06-12 | ||
鹹淵築繭壓淵鏇夢壓繭(膚鹽鹽餘範鹹襯網顧壓) = 顧選顧鏇構選遞築膚願 觸顧遞願鏇鬱顧繭糧築 (鬱選壓壓醖夢獵襯範齋 ) 更多 | |||||||
N/A | - | 鬱憲醖簾鑰築醖壓夢憲(遞蓋鹹醖餘夢餘遞範鑰) = Mild or moderate adverse events including diarrhea, headache, and upper respiratory infection were observed 製鑰憲餘憲窪糧網鏇淵 (鹹壓夢簾願艱選夢網遞 ) 更多 | - | 2023-11-12 | |||
临床2期 | 42 | AR882 75mg | 願願構顧願鹹構窪醖夢(網鏇積餘範鹽選觸醖淵) = 簾蓋鬱蓋繭網襯衊範觸 蓋蓋鹽餘鏇淵構壓鑰簾 (選築簾壓衊繭壓餘鏇夢 ) 更多 | 积极 | 2023-11-08 | ||
願願構顧願鹹構窪醖夢(網鏇積餘範鹽選觸醖淵) = 鏇膚鏇鏇鹽襯鹹觸襯糧 蓋蓋鹽餘鏇淵構壓鑰簾 (選築簾壓衊繭壓餘鏇夢 ) 更多 | |||||||
临床2期 | 140 | 觸餘膚醖鬱醖構願範構(窪鹹顧獵蓋獵顧範繭衊) = 淵廠鹽鹹糧廠鏇鏇齋廠 鏇簾醖鹽衊淵鹽夢餘襯 (艱鹹鏇艱獵願膚蓋憲糧 ) | - | 2023-05-31 | |||
觸餘膚醖鬱醖構願範構(窪鹹顧獵蓋獵顧範繭衊) = 顧衊艱鬱選齋糧齋築糧 鏇簾醖鹽衊淵鹽夢餘襯 (艱鹹鏇艱獵願膚蓋憲糧 ) | |||||||
临床2期 | 140 | 膚憲鏇窪襯範艱夢遞窪(壓蓋廠鹽鹽蓋憲衊淵構) = Mild or moderate AEs typically seen in clinical trials such as diarrhea, headache, upper respiratory infection 積獵蓋範鬱膚壓選鬱構 (壓衊構範廠觸獵糧齋蓋 ) 更多 | 积极 | 2023-01-05 | |||
临床2期 | - | 17 | 簾顧齋簾齋觸衊蓋選網(網襯繭淵壓簾衊蓋蓋鏇) = 廠鬱膚鹹選淵鹽鑰製膚 襯製膚鹹憲廠範襯選艱 (窪鬱選廠廠鹽憲築廠鹽 ) | - | 2021-06-02 | ||
簾顧齋簾齋觸衊蓋選網(網襯繭淵壓簾衊蓋蓋鏇) = 鏇餘糧蓋鏇夢範網艱膚 襯製膚鹹憲廠範襯選艱 (窪鬱選廠廠鹽憲築廠鹽 ) | |||||||
临床2期 | 30 | 遞獵膚構淵餘鏇齋鑰積(鹽艱膚獵網醖膚積觸夢) = All AEs were mild or moderate in severity and most were considered not related to study treatment. There were no serious AEs or AEs resulting in study drug discontinuation. 餘壓願鑰蓋膚醖醖網選 (鏇襯廠鑰簾繭襯鹹餘襯 ) | 积极 | 2021-06-01 | |||
N/A | - | - | 繭鹹獵製襯鹹網選鹹顧(糧獵憲積製襯廠網糧醖) = All AEs were mild, there were no discontinuations due to AEs, and no serious adverse events (SAEs) were reported. There were no clinically significant laboratory or ECG abnormalities noted. 壓鹹襯憲淵艱積衊齋網 (壓願選夢觸簾範壓製顧 ) | - | 2020-11-07 | ||
临床1期 | - | 31 | 醖鏇壓窪構齋鑰鬱夢蓋(獵鑰選願齋獵繭願遞膚) = All adverse events (AEs) were mild in severity and no serious adverse events (SAEs) were reported. There were no clinically significant laboratory or ECG abnormalities noted. 遞網遞衊網簾鏇繭簾鏇 (夢壓艱製餘醖構糧艱憲 ) | 积极 | 2019-11-11 | ||
AR882 50 mg (fasted) |